Neuralink
PrivateLast Round
Series E
May 27, 2025
Est. Valuation
$9.6B
Total Funding Raised
$1.26B
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Neuralink is a neurotechnology company that develops implantable brain-machine interfaces aimed at assisting individuals with paralysis and addressing neurological conditions while potentially enhancing cognitive abilities.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials, Medical AI
Business Model
B2B2C
Customer Profile
Hardware Sales, Subscription SaaS, Data as a Service
AI Layer
Application
Keywords
Price History
Caplight MarketPrice™ estimate for Neuralink, published with a 90-day delay.
Caplight MarketPrice™
$315.75
per share, as of July 2026
+660.1%
2-year change
The most recent months of MarketPrice™ are available to Caplight clients.
Caplight MarketPrice™ is an estimate of private secondary market pricing, shown here on a delayed basis for illustrative purposes only. It may be incomplete, is subject to change, and may not be relied upon for any purpose or considered investment advice.
Neuralink Comparables
Compare Neuralink with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Synchron | 85% | |
| Paradromics | 84% | |
| Precision Neuroscience | 81% |
For institutional investors. Book with your work email.
Neuralink Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | May 27, 2025 | ||||
| Series D Extension | Nov 22, 2023 | ||||
| Series D | Aug 5, 2023 | ||||
| Series C | Jul 29, 2021 | ||||
| Series B | May 10, 2019 | ||||
Series A | Aug 25, 2017 |
For institutional investors. Book with your work email.
Secondary Market Activity
Bids, offers, and trades by month
| Operation | Date | Price | Size | Share Class | Structure |
|---|---|---|---|---|---|
OFFER | |||||
OFFER | |||||
OFFER | |||||
BID | |||||
OFFER |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Neuralink Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Human Capital | Series E |
| Time BioVentures | Series C |
| GV | Series C |
| Craft Ventures | Series C, Series B |
| CoreNest | Series E |
| Founders Fund | Series C, Series E, Series D, Series D Extension |
| Thrive Capital | Series E |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- May 10, 2026
Designs have served over 20 individuals to date.
- May 10, 2026
Telepathy Product enables typing at 35 WPM for paralyzed individuals.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 3, 2026
Neuralink is developing Blindsight to deliver visual information through an implant.
- launchesOct 30, 2026
Neuralink launches Telepathy and Blindsight, medical brain-computer interface technologies designed to support thought-driven digital interactions, motor control, and visual perception.
- integrates_withOct 29, 2026
Neuralink integrates Apple, Inc. with Bloom so BCI-decoded speech enters the call microphone stream, while Bloom remains a research and trial tool with no public release date announced.
- is_developingOct 21, 2026
Neuralink is developing brain-computer interfaces (BCIs) that record neural activity and translate it into commands for controlling external devices, including computers, phones and other devices.
- expands_offices_toOct 13, 2026
Neuralink expands into the United Kingdom, bringing its investigational brain-computer interface into additional clinical settings, with University College London Hospitals reporting its first UK participant’s operation in Oct '25.
For institutional investors. Book with your work email.
Neuralink Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Appears On
Curated lists and screens where this company is featured.
Frequently Asked Questions
Common questions about Neuralink's valuation, stock price, and market status.
Is Neuralink a public or private company?
Neuralink is a private company.
What is the current stock price of Neuralink?
Neuralink is a private company, so its shares have no public market price. Caplight tracks Neuralink's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Neuralink worth (valuation)?
Neuralink's valuation is estimated at $9.6B based on funding round data.
Can I buy Neuralink stock?
Neuralink shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Neuralink's last funding round?
Neuralink's most recent funding round was Series E on May 27, 2025.
Who are the main investors in Neuralink?
Key investors in Neuralink include Founders Fund, Vy Capital.
Will Neuralink IPO soon?
No public IPO plans have been announced for Neuralink.
How can I track Neuralink secondary market activity?
Caplight tracks bids, offers, and trades in Neuralink's shares on secondary markets.